Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
BioSpace · BioSpace
Audio is streamed directly from the publisher (api.riverside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing therapy from Vertex and CRISPR Therapeutics, and bluebird bio’s Lyfgenia, which comes with a hefty price tag and a black box warning.
Axcella announced its closure; what does the future of long-covid treatments look like, especially as attention shifts to different markets like ADCs and neurological treatments?
Also discussed - Vanda drops $100m on rights to MS drug Ponvory, AI regulatory developments in Europe.
BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.